OBJECTIVE： To study the pharmacokinetics of the active ingredients of Shenmai injection， including ginsenoside Rg1 and ginsenoside Re， in normal Beagle dogs and those with myocardial ischemia. METHODS： 6 Beagle dogs were given isoproterenol hydrochloride （1.1 mg/kg） sc to establish the model of myocardial ischemia （model group）. Another 6 Beagle dogs were given isometric normal saline （2.2 ml/kg） sc as controls group. The two groups of dogs respectively received corresponding drugs sc at 8：00 am and 13：00 pm on day 1 and at 8：00 am on day 2. Each group of dogs were given Shenmai injection （1.6 ml/kg） iv 1 h after administration on day 2， and such intravenous drip lasted for about 1 h. Blood was collected from each group 0，0.25， 0.5， 0.75， 1 （the end of iv）， 1.5， 2， 3， 4， 6， 8， 12 and 24 h from the start of iv. Liquid chromatography-mass spectrometry was adopted to determine the concentrations of ginsenoside Rg1 and ginsenoside Re in blood， and WinNonlin 6.3 was used to calculate pharmacokinetic parameters for comparison. RESULTS： For ginsenoside Re in the dogs of the model group， t1/2 was （2.69±1.12） h， AUC0-24 h was （2 060.78±812.18） h·μg/L， Vz was （46.16±20.98） ml and CL was （9.02±4.45） ml/h； compared to the normal control group， AUC0-24 h was much greater and Vz and CL were significantly lower， showing a statistically significant difference （P＜0.05）. No significant difference in the pharmacokinetic parameters of ginsenoside Rg1 was shown between 2 groups（P＞0.05）. CONCLUSIONS： Myocardial ischemia may affect the removal of ginsenoside Re in Beagle dogs， but has no effect on the pharmacokinetic process of ginsenoside Rg1.